Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital.
Clostridioides difficile infection
faecal microbiota transplantation
Journal
Therapeutic advances in gastroenterology
ISSN: 1756-283X
Titre abrégé: Therap Adv Gastroenterol
Pays: England
ID NLM: 101478893
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
04
2020
accepted:
25
05
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Faecal microbiota transplantation (FMT) is a reasonable therapeutic option for the treatment of This prospective study collects the clinical and laboratory data of RCDI patients treated with FMT by colonoscopy from February 2016 to October 2019. Stool samples for metagenomic analysis were collected pre-FMT at 1 week and at 6 and 12-24 months post-FMT. In the study period, 20 FMT procedures were performed on 19 patients. Overall, FMT was effective in 85% of treated patients. No serious adverse event was recorded. In the medium- to long-term follow up, a newly diagnosed case of collagenous colitis was observed. Post-FMT, significant changes in microbiota were observed, characterised by the transition from a low- to a greater-diversity profile. Therefore, FMT restores eubiosis and maintains it over time. FMT is a safe and effective treatment option in RCDI patients. This procedure induces profound microbiota changes that explain its high clinical efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
Faecal microbiota transplantation (FMT) is a reasonable therapeutic option for the treatment of
METHODS
METHODS
This prospective study collects the clinical and laboratory data of RCDI patients treated with FMT by colonoscopy from February 2016 to October 2019. Stool samples for metagenomic analysis were collected pre-FMT at 1 week and at 6 and 12-24 months post-FMT.
RESULTS
RESULTS
In the study period, 20 FMT procedures were performed on 19 patients. Overall, FMT was effective in 85% of treated patients. No serious adverse event was recorded. In the medium- to long-term follow up, a newly diagnosed case of collagenous colitis was observed. Post-FMT, significant changes in microbiota were observed, characterised by the transition from a low- to a greater-diversity profile. Therefore, FMT restores eubiosis and maintains it over time.
CONCLUSION
CONCLUSIONS
FMT is a safe and effective treatment option in RCDI patients. This procedure induces profound microbiota changes that explain its high clinical efficacy.
Identifiants
pubmed: 32774464
doi: 10.1177/1756284820934315
pii: 10.1177_1756284820934315
pmc: PMC7391433
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1756284820934315Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Trends Biotechnol. 2015 Sep;33(9):496-503
pubmed: 26210164
Aliment Pharmacol Ther. 2015 Oct;42(8):1011-8
pubmed: 26264455
Ann Intern Med. 2019 Nov 19;171(10):695-702
pubmed: 31683278
Therap Adv Gastroenterol. 2019 Apr 10;12:1756284819843002
pubmed: 31007720
Curr Gastroenterol Rep. 2013 Aug;15(8):337
pubmed: 23852569
Nat Rev Gastroenterol Hepatol. 2016 Sep;13(9):508-16
pubmed: 27329806
Infect Control Hosp Epidemiol. 2010 May;31(5):431-55
pubmed: 20307191
J Clin Gastroenterol. 2014 Sep;48(8):693-702
pubmed: 24440934
BMC Med. 2016 Oct 11;14(1):155
pubmed: 27724956
Gut. 2017 Apr;66(4):569-580
pubmed: 28087657
BMC Gastroenterol. 2018 Aug 28;18(1):131
pubmed: 30153805
Ann Transl Med. 2018 Feb;6(3):39
pubmed: 29610731
Aliment Pharmacol Ther. 2017 Sep;46(5):479-493
pubmed: 28707337
Gastroenterology. 2012 Mar;142(3):490-6
pubmed: 22155369
Front Microbiol. 2018 Aug 14;9:1835
pubmed: 30154767
Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1731-1735
pubmed: 31165961
Gut. 2018 Sep;67(9):1716-1725
pubmed: 29934437
Aliment Pharmacol Ther. 2014 May;39(10):1003-32
pubmed: 24641570
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Aliment Pharmacol Ther. 2019 Feb;49(4):354-363
pubmed: 30628108